Turbine Raises $25M Series B, Expands into Immunology with New Pharma Partnership

Turbine has raised $25 million in Series B financing led by Interactive Venture Partners, with participation from Beiersdorf Venture Capital and existing investors including MSD Global Health Innovation, Accel, and Mercia, announced in a press release.

The funding will support the expansion of Turbine’s AI-powered virtual cell platform across new assay types in discovery and translational medicine. The company’s lab-in-the-loop technology will generate proprietary datasets to enhance its foundational virtual cell model, which powers its no-code Virtual Lab platform used by pharmaceutical partners.

Alongside the funding, Turbine announced its first immunology-focused partnership with a top 10 pharmaceutical company. Under the collaboration, Turbine’s virtual assays will be trained to simulate immune cell behavior using proprietary data from the partner. The goal is to identify and prioritize novel therapeutic combinations by running large-scale in silico experiments within the Virtual Lab.

The new partnership marks Turbine’s expansion beyond oncology into immunology, enabling researchers to explore complex immune pathways and test hypotheses computationally before laboratory validation.